☆ 4.7 Article

Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab-A Preliminary Study

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Surgery

Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients

Boonphiphop Boonpheng et al.

Summary: This study aimed to investigate the use of TCZ as a treatment option for ca-AMR. The results showed that TCZ can reduce graft injury caused by chronic active antibody-mediated rejection and modulate the immune response, while stabilizing graft function and reducing proteinuria. Overall, the study highlights the potential effectiveness of TCZ in treating ca-AMR. Rating: 8 points

CLINICAL TRANSPLANTATION (2023)

Add to Collection

Article Surgery

Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients

Pascale Khairallah et al.

Summary: Treatment of CAAMR with tocilizumab was associated with a decrease in the rate of eGFR decline and a reduction in interstitial inflammation scores in patients with CAAMR.

CLINICAL TRANSPLANTATION (2023)

Add to Collection

Article Surgery

Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe

Lionel P. E. Rostaing et al.

Summary: Antibody mediated rejection (ABMR) is the leading cause of late allograft failure following kidney transplantation. The study evaluated current practices in Europe for post-transplant surveillance and management of chronic active ABMR (CABMR). A survey found that clinical measures of graft function are the main focus of post-transplant surveillance, but this may lead to late diagnoses and inadequate treatment options.

TRANSPLANT INTERNATIONAL (2023)

Add to Collection

Review Transplantation

Anti-Interleukin 6 Therapeutics for Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients

Rajeev Sharma

Summary: Chronic antibody-mediated rejection is a major cause of late renal allograft loss, with no approved treatment. Current standard treatment protocols are based on expert consensus rather than scientific evidence and have low success rates. This review focuses on the biologic basis, safety, and efficacy of interleukin 6 inhibitors, tocilizumab and clazakizumab, for treating chronic antibody-mediated rejection in kidney transplant recipients.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION (2022)

Add to Collection

Article Medicine, General & Internal

Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization

Aurelie Truffot et al.

Summary: The presence of anti-HLA antibodies is a growing challenge in kidney transplantation. Tocilizumab, a potential supplement to conventional desensitization therapy, was studied for its plasma trough concentrations and the relationship with the evolution of anti-HLA antibodies.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Immunology

Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review

Lara Cabezas et al.

Summary: Chronic kidney disease is a significant public-health problem, and kidney transplantation is a better alternative to dialysis. Antibody-mediated rejection is a major complication following kidney transplantation. TCZ appears to be a safe and effective treatment for managing antibody-mediated rejection and reducing injury.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Surgery

Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients

Meghan Pearl et al.

Summary: Tocilizumab therapy in pediatric renal transplant recipients with refractory AMR is well tolerated and can stabilize renal function.

CLINICAL TRANSPLANTATION (2022)

Add to Collection

Review Immunology

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

Jan Miroslav Hartinger et al.

Summary: This review provides a description of the pharmacokinetics and pharmacodynamics of rituximab (RTX) in various glomerulopathies, as well as the impact of proteinuria, anti-drug antibodies, and other clinical variables on its clearance and distribution. The review also discusses the role of complement levels, therapeutic drug monitoring, dosing implications, and the potential efficacy of alternative anti-CD20 molecules in RTX unresponsive patients.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Investigational drugs for the treatment of kidney transplant rejection

Lukas K. van Vugt et al.

Summary: Kidney transplant rejection remains a clinical problem, and current therapy is unsatisfactory. This review discusses novel and investigational drugs for the treatment of kidney transplant rejection, as well as potential therapeutic strategies and future directions.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Add to Collection

Article Surgery

Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial

Sindhu Chandran et al.

Summary: In this study, the blockade of IL-6 with tocilizumab showed promising results in controlling T cell alloimmune response in kidney transplant recipients by increasing Tregs frequency, dampening Teff function, and reducing graft inflammation.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Article Surgery

Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?

Maeva Massat et al.

Summary: This study found that monthly infusions of tocilizumab did not alter the progression of antibodies in patients with antibody-mediated rejection resistant to standard of care therapy. There were no significant differences in graft survival and decline in renal function between patients who received tocilizumab and those who did not. Despite a decrease in inflammation and tubulitis scores, the course of antibody-mediated lesions and chronic glomerulopathy were similar in both groups.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Review Pharmacology & Pharmacy

Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis

Aurelie Truffot et al.

Summary: For patients with rheumatoid arthritis (RA) treated in the second line, serum concentrations of rituximab (RTX) and tocilizumab (TCZ) show high variability, with no demonstrated link between concentration and clinical response.

FUNDAMENTAL & CLINICAL PHARMACOLOGY (2021)

Add to Collection

Review Surgery

Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review

Allyson Hart et al.

Summary: Cohort studies of kidney transplant recipients show that AMR is common and linked to increased risk of death-censored graft failure, but there is wide variation in populations, definitions, and reported incidence, with gaps in understanding refractory AMR, its costs, and resulting quality of life.

CLINICAL TRANSPLANTATION (2021)

Add to Collection

Review Medicine, General & Internal

Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?

Lucia Del Vecchio et al.

Summary: Rituximab, as a widely recommended treatment for nephrotic syndromes, has shown efficacy and safety in idiopathic membranous nephropathy. However, its efficacy and treatment schedules in adults with nephrotic syndrome remain a matter of debate, with a large interindividual variability in response. High resolution flow cytometry has been suggested as a useful tool for better understanding reasons of rituximab failure or avoiding unnecessary retreatments.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring

Johan Noble et al.

Summary: In this study, tocilizumab (TCZ) showed potential in preventing clinical and histological deterioration of chronic antibody-mediated rejection (cABMR) in kidney transplant recipients, but its effectiveness may be limited in patients with more severe conditions. Randomized studies are needed to further evaluate the risk/benefit profile of TCZ in cABMR.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Review Critical Care Medicine

Interleukin-6: obstacles to targeting a complex cytokine in critical illness

Oliver J. McElvaney et al.

Summary: IL-6 is a pleiotropic cytokine that plays a dual role in both inflammation and anti-inflammatory functions. Understanding the complex signaling processes of IL-6 is crucial for accurately interpreting its concentrations in blood or lungs, utilizing it as a critical care biomarker, and designing effective anti-IL-6 strategies.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome

Yewei Chen et al.

Summary: The study aimed to investigate the pharmacokinetics of rituximab in pediatric patients with FRNS/SDNS, showing a significant increase in drug clearance in this patient population. It suggests that higher doses or more frequent regimens of rituximab may be needed for optimal therapeutic effects in patients with FRNS/SDNS, warranting further clinical studies with more patients to confirm this result.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Surgery

IL-6 Directed Therapy in Transplantation

Cynthia L. Miller et al.

Summary: IL-6 plays a crucial role in allograft injury after solid organ transplantation. Blocking the IL-6/IL-6R signaling pathway has shown promising results in mitigating harmful effects, with available agents including monoclonal antibodies and janus kinase inhibitors. Clinical trials have demonstrated the efficacy of IL-6 blockade in kidney transplant recipients, with ongoing studies exploring its potential in other types of solid organ transplantation.

CURRENT TRANSPLANTATION REPORTS (2021)

Add to Collection

Article Immunology

Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection

Bong-Ha Shin et al.

TRANSPLANTATION (2020)

Add to Collection

Article Surgery

The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection

Alexandre Loupy et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2020)

Add to Collection

Article Surgery

Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation

Antonio Lavacca et al.

CLINICAL TRANSPLANTATION (2020)

Add to Collection

Article Transplantation

Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients

April A. Pottebaum et al.

TRANSPLANTATION DIRECT (2020)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components

Carla Bastida et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Article Rheumatology

Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis

Uri Arad et al.

JOURNAL OF RHEUMATOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy

Uma Fogueri et al.

ANNALS OF PHARMACOTHERAPY (2019)

Add to Collection

Article Chemistry, Analytical

A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease

Theo Willeman et al.

ANALYTICA CHIMICA ACTA (2019)

Add to Collection

Article Surgery

Antibody-mediated rejection: New approaches in prevention and management

R. A. Montgomery et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2018)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in PatientsWith Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA

Hisham Abdallah et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

Add to Collection

Article Rheumatology

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study

E. L. Kneepkens et al.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2017)

Add to Collection

Article Surgery

Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients

J. Choi et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2017)

Add to Collection

Editorial Material Immunology

The Challenge of Acute Antibody-Mediated Rejection in Kidney Transplantation

Hassib Chehade et al.

TRANSPLANTATION (2016)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

Miroslav Dostalek et al.

CLINICAL PHARMACOKINETICS (2013)

Add to Collection

Editorial Material Medicine, General & Internal

被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Urology & Nephrology

Association between Albuminuria, Kidney Function, and Inflammatory Biomarker Profile in CKD in CRIC

Jayanta Gupta et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)

Add to Collection

Article Transplantation

Inflammation, kidney function and albuminuria in the Framingham Offspring cohort

Ashish Upadhyay et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.